These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 12497098)

  • 1. Prostate specific antigen measurements after minimally invasive surgery of the prostate in men with benign prostatic hypertrophy.
    Shingleton WB; Terrell F; Kolski J; May W; Renfroe DL; Fowler JE
    Prostate Cancer Prostatic Dis; 2000 Nov; 3(3):200-202. PubMed ID: 12497098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.
    Helfand BT; Anderson CB; Fought A; Kim DY; Vyas A; McVary KT
    Urology; 2009 Jul; 74(1):177-83. PubMed ID: 19428074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altered prostate specific antigen reference range after transurethral resection of the prostate.
    Wolff JM; Boekels O; Borchers H; Jakse G; Rohde D
    Anticancer Res; 2000; 20(6D):4977-80. PubMed ID: 11326651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in serum prostate-specific antigen level after prostatectomy in patients with benign prostatic hyperplasia.
    Hosseini SY; Salimi M; Hosseini Moghaddam SM
    Urol J; 2005; 2(4):183-8. PubMed ID: 17602426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of transurethral resection of the prostate in "asymptomatic" patients with an elevated prostate-specific antigen level.
    van Renterghem K; Van Koeveringe G; Achten R; Van Kerrebroeck P
    Eur Urol; 2007 Sep; 52(3):819-26. PubMed ID: 17418482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostatic-specific antigen velocity after holmium laser enucleation of the prostate: possible predictor for the assessment of treatment effect durability for benign prostatic hyperplasia and detection of malignancy.
    Elmansy HM; Elzayat EA; Sampalis JS; Elhilali MM
    Urology; 2009 Nov; 74(5):1105-10. PubMed ID: 19773035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term results of contact laser versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia with small or moderately enlarged prostates.
    Tuhkanen K; Heino A; Aaltomaa S; Ala-Opas M
    Scand J Urol Nephrol; 2003; 37(6):487-93. PubMed ID: 14675922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
    Zhao Z; Liu J; Li S; Shen W
    Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Probability of finding T1a and T1b (incidental) prostate cancer during TURP has decreased in the PSA era.
    Jones JS; Follis HW; Johnson JR
    Prostate Cancer Prostatic Dis; 2009; 12(1):57-60. PubMed ID: 18379587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of standard transurethral resection, transurethral vapour resection and holmium laser enucleation of the prostate for managing benign prostatic hyperplasia of >40 g.
    Gupta N; Sivaramakrishna ; Kumar R; Dogra PN; Seth A
    BJU Int; 2006 Jan; 97(1):85-9. PubMed ID: 16336334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years.
    Te AE; Malloy TR; Stein BS; Ulchaker JC; Nseyo UO; Hai MA
    BJU Int; 2006 Jun; 97(6):1229-33. PubMed ID: 16686717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does transurethral resection of prostate (TURP) affect outcome in patients who subsequently develop prostate cancer?
    D'Ambrosio DJ; Ruth K; Horwitz EM; Chen DY; Pollack A; Buyyounouski MK
    Urology; 2008 May; 71(5):938-41. PubMed ID: 18279939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME
    Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of prostate stem cell antigen (PSCA) mRNA expression and subsequent prostate cancer risk in men with benign prostatic hyperplasia following transurethral resection of the prostate.
    Zhigang Z; Wenlu S
    Prostate; 2008 Feb; 68(2):190-9. PubMed ID: 18076024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term clinical outcome of diagnostic transurethral resection of the prostate in patients with elevated prostate-specific antigen level and minor lower urinary tract symptoms.
    van Renterghem K; van Koeveringe G; Achten R; van Kerrebroeck P
    Urol Int; 2009; 83(1):60-5. PubMed ID: 19641361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and factors predicting the detection of prostate cancer after transurethral resection of the prostate for clinically benign disease.
    Bright EA; Manuel C; Goddard JC; Khan MA
    Urol Int; 2009; 83(2):171-4. PubMed ID: 19752612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer.
    Mitchell DM; Swindell R; Elliott T; Wylie JP; Taylor CM; Logue JP
    Radiother Oncol; 2008 Jul; 88(1):102-7. PubMed ID: 18453022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate-specific antigen (PSA) velocity and benign prostate hypertrophy predict for PSA spikes following prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Lief JH; Hinerman-Mulroy A; Galbreath RW
    Brachytherapy; 2003; 2(3):181-8. PubMed ID: 15062141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.